share_log

Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability

Benzinga ·  Sep 30 04:00

$Medtronic (MDT.US)$, a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.

Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia.

"Real-world evidence on chronic lesion formation and durability is critical as use of PFA...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment